Meridian Bioscience, Inc.
Catherine is an experienced global healthcare executive and board member. She is Chief Business Officer at Strata Oncology, Inc., a precision medicine company, where she is part of the senior executive team and manages corporate and business development, marketing, public relations, clinical operations and legal. She is also an independent director and member of the Audit Committee of the Board of Directors of Meridian Bioscience, Inc. (NASDAQ: VIVO), a diagnostics and life sciences company, and serves on the Advisory Board of Neurocern, Inc., a dementia population health company. Catherine is involved in several volunteer organizations, including Chicago Innovation Mentors @ MATTER, supporting healthcare startups within the MATTER incubator and in the broader community of university and clinical research institutions; the Life Sciences Advisory Council of Springboard Enterprises, which supports female entrepreneurs.
Catherine previously held senior corporate roles at Takeda Pharmaceuticals and Abbott Laboratories in corporate and business development, legal, compliance, and global finance functions. She led strategy development and deal execution in transformative M&A (e.g., Takeda $13B acquisition of Nycomed S.A. for geographic expansion; Takeda $9B acquisition of Millennium Pharmaceuticals for enhanced oncology revenue and capabilities; Abbott $7B acquisition of Knoll Laboratories, expanding global presence and assets including mega‐ blockbuster Humira). She also built and led business development teams in R&D and commercial collaborations, across multiple therapeutic areas such as CNS, cardiovascular, metabolic, GI, renal, respiratory and immunology, continuing to take hands-on responsibility in structuring, diligence, negotiation and governance of critical partnerships. Catherine also led global restructuring and organization design (e.g., achieving WW cross-functional recurring savings of >$500 MM while reporting to Global CFO; global organization design, build, and management as senior member of Abbott Office of Ethics & Compliance), conducted enterprise risk assessments and internal investigations, and created strategy and led execution of successful litigation including antitrust, IP, employment, mass tort, as well as shareholder and government actions.
In addition to her corporate work, Catherine previously provided advisory and consulting services on strategy development, corporate development, transactions and other aspects of building and growing a business. Her clients included a specialty pharmaceutical company in women’s health, a mobile health company in pharmaceutical clinical research, and a startup company developing novel pain management therapy.